122
Views
7
CrossRef citations to date
0
Altmetric
Letter

Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells

, , &
Pages 1097-1100 | Received 03 Jul 2012, Accepted 30 Jul 2012, Published online: 04 Sep 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Shadia Zaman, Rui Wang & Varsha Gandhi. (2014) Targeting the apoptosis pathway in hematologic malignancies. Leukemia & Lymphoma 55:9, pages 1980-1992.
Read now

Articles from other publishers (6)

Natalie Yan Li Ngoi, Clarice Choong, Joanne Lee, Gregory Bellot, Andrea LA Wong, Boon Cher Goh & Shazib Pervaiz. (2020) Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer. Cancers 12:3, pages 574.
Crossref
Ruinian Zheng, Kexu Chen, Yu Zhang, Jie Huang, Fengrong Shi, Gang Wu & Senming Wang. (2017) Apogossypolone induces apoptosis and autophagy in nasopharyngeal carcinoma cells in an in vitro and in vivo study. Oncology Letters 14:1, pages 751-757.
Crossref
Jie Ji, Benigno C. Valdez, Yang Li, Yan Liu, Esmeralda C. Teo, Yago Nieto, Richard E. Champlin & Borje S. Andersson. (2016) Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study. Experimental Hematology 44:6, pages 458-465.
Crossref
Jens Mani, Stefan Vallo, Stefanie Rakel, Patrick Antonietti, Florian Gessler, Roman Blaheta, Georg Bartsch, Martin Michaelis, Jindrich Cinatl, Axel Haferkamp & Donat Kögel. (2015) Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (−)-Gossypol (AT-101). BMC Cancer 15:1.
Crossref
Kumudha Balakrishnan & Varsha Gandhi. (2013) Bcl-2 antagonists: a proof of concept for CLL therapy. Investigational New Drugs 31:5, pages 1384-1394.
Crossref
Christian Billard. (2013) BH3 Mimetics: Status of the Field and New Developments. Molecular Cancer Therapeutics 12:9, pages 1691-1700.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.